These novel therapies , Semaglutide , represent a remarkable advancement in treating metabolic dysfunction and potentially associated ailments . These drugs are grouped as GLP-1 pathway stimulators, meaning they function to mimic the endogenous GLP-1 substance , enhancing metabolic secretion and suppressing appetite . Despite Retatrutide each one w